Stay updated with breaking news from Purple biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC) based on preliminary interim dataProlongation of ....
Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter Phase 2 study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma presented. ....
ASCO: Early Purple Biotech data gain ground in metastatic pancreatic cancer fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Purple Biotech Ltd (NASDAQ:PPBT – Free Report) – Stock analysts at HC Wainwright reduced their Q3 2024 EPS estimates for Purple Biotech in a research report issued on Tuesday, May 21st. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.13) for the quarter, down from their previous […] ....
Purple Biotech's (PPBT) Buy Rating Reaffirmed at HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.